Results 81 to 90 of about 41,944 (264)

Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells [PDF]

, 2016
PURPOSE: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are low and treatment options are limited to chemotherapy and hormonal therapy.
Mairs, Robert J., Rae, Colin
core   +2 more sources

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

BMC Cancer, 2020
Background Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) which inhibits binding of programmed cell death ligand
Jean-David Fumet, Emeric Limagne, Marion Thibaudin, Caroline Truntzer, Aurélie Bertaut, Emilie Rederstorff, Francois Ghiringhelli   +6 more
doaj   +1 more source

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial

Nature Communications
Endometrial cancers are characterized by frequent alterations in the PI3K-AKT-mTor, IGF1 and DNA repair signaling pathways. Concomitant inhibition of these pathways was warranted.
Max Piffoux, A. Leary, Philippe Follana, C. Abdeddaim, Florence Joly, S. Bin, M. Bonjour, Anais Boulai, C. Callens, Laurent Villeneuve, Marine Alexandre, V. Schwiertz, G. Freyer, M. Rodrigues, Benoît You   +14 more
semanticscholar   +1 more source

Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors

Advanced Science, EarlyView.
This study presents the first ubiquitin‐specific protease 1 (USP1) allosteric fluoroprobe and fluorescence polarization assay, enabling the differentiation of allosteric and catalytic site inhibitors. Further, a novel class of tetrahydroisoquinoline‐based USP1 inhibitors is designed, with compound 14a (USP1 IC50 = 29.9 nM) showing strong selectivity ...
Jiawei Cheng, Peipei Wang, Pengfei Wang, Jiamin Wang, Baiyang Li, Daqing Fang, Jian He, Xiaobei Hu, Weijuan Kan, Yubo Zhou, Chunpu Li, Jia Li, Hong Liu   +12 more
wiley   +1 more source

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

The Lancet Oncology, 2020
BACKGROUND Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in patients ...
S. Domchek, S. Postel-Vinay, S. Im, Yeon-Hee Park, J. Delord, A. Italiano, J. Alexandre, B. You, S. Bastian, M. Krebs, Ding Wang, S. Waqar, M. Lanasa, J. Rhee, Hai-Cheng Gao, V. Rocher-Ros, E. V. Jones, Sakshi Gulati, A. Coenen-Stass, I. Kozarewa, Z. Lai, H. Angell, L. Opincar, P. Herbolsheimer, B. Kaufman   +24 more
semanticscholar   +1 more source

Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells

Molecular Oncology, 2018
A number of prostate cancer (PCa)‐specific genomic aberrations (denominated BRCAness genes) have been discovered implicating sensitivity to PARP inhibition within the concept of synthetic lethality.
Gertrud E. Feiersinger, Kristina Trattnig, Peter D. Leitner, Fabian Guggenberger, Alexander Oberhuber, Sarah Peer, Martin Hermann, Ira Skvortsova, Jana Vrbkova, Jan Bouchal, Zoran Culig, Frédéric R. Santer   +11 more
doaj   +1 more source

EXTH-08. REPLACEMENT OF MICROGLIA BY BRAIN-ENGRAFTED MACROPHAGES PREVENTS MEMORY DEFICITS AFTER THERAPEUTIC WHOLE-BRAIN IRRADIATION [PDF]

, 2019
Microglia have a distinct origin compared to blood circulating myeloid cells. Under normal physiological conditions, microglia are maintained by self-renewal, independent of hematopoietic progenitors. Following genetic or pharmacologic depletion, newborn
Boosalis, Zoe, Chen, David, Feng, Xi, Gupta, Nalin, Gupta, Sonali, Liu, Sharon, Rosi, Susanna   +6 more
core   +1 more source

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2 [PDF]

, 2017
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). Methods: Eligible
Bell-McGuinn, Katherine, Brenton, James D., Castro, Cesar M., Chen, Lee-may, Coleman, Robert L., Giordano, Heidi, Goble, Sandra, Konecny, Gottfried E., Kristeleit, Rebecca S., Leary, Alexandra, Lin, Kevin K., Ma, Ling, Maloney, Lara, Mcneish, Iain A., Oaknin, Ana, Oza, Amit M., O’Malley, David M., Provencher, Diane, Raponi, Mitch, Ray-Coquard, Isabelle, Rolfe, Lindsey, Shapira-Frommer, Ronnie, Sun, James, Swisher, Elizabeth M., Tinker, Anna V.   +24 more
core   +1 more source

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Journal of Clinical Oncology, 2023
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial. PURPOSE Phase III PROfound trial (ClinicalTrials.gov identifier: NCT02987543) met its primary and key secondary objectives ...
J. Mateo, Johann S. de Bono, K. Fizazi, Fred Saad, N. Shore, S. Sandhu, Kim N. Chi, N. Agarwal, David Olmos, A. Thiery-Vuillemin, M. Özgüroğlu, N. Mehra, N. Matsubara, Jae Young Joung, Charles Padua, Ernesto Korbenfeld, Jinyu Kang, Helen Marshall, Zhongwu Lai, A. Barnicle, C. Poehlein, N. Lukashchuk, M. Hussain   +22 more
semanticscholar   +1 more source